SLNO
Soleno Therapeutics Inc.
$52.00
+$2.51(+5.07%)
47
Overall
55
Value
40
Tech
47
Quality
Market Cap
$2.54B
Volume
1.45M
52W Range
$41.50 - $90.32
Target Price
$113.83
Company Overview
| Mkt Cap | $2.54B | Price | $52.00 |
| Volume | 1.45M | Change | +5.07% |
| P/E Ratio | -14.5 | Open | $49.80 |
| Revenue | -- | Prev Close | $49.49 |
| Net Income | $-175.8M | 52W Range | $41.50 - $90.32 |
| Div Yield | N/A | Target | $113.83 |
| Overall | 47 | Value | 55 |
| Quality | 47 | Technical | 40 |
No chart data available
About Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Sector: Healthcare
Industry: Diagnostics & Research
Latest News
CRNX, CYTK, MDGL, SLNO: Top Analyst Outlines Her ‘Top Biotech Ideas for 2026’
Shalu Saraf•6 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SLNO | $52.00 | +5.1% | 1.45M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Soleno Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW